FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366000488> ?p ?o ?g. }

• W4366000488 abstract "BackgroundInflammation is a key driver of heart failure with preserved left ventricular ejection fraction. AZD4831 inhibits extracellular myeloperoxidase, decreases inflammation, and improves microvascular function in preclinical disease models.Methods and ResultsIn this double-blind phase 2a study (Safety and Tolerability Study of AZD4831 in Patients With Heart Failure [SATELLITE]; NCT03756285), patients with symptomatic heart failure, left ventricular ejection fraction of ≥40%, and elevated B-type natriuretic peptides were randomized 2:1 to once-daily oral AZD4831 5 mg or placebo for 90 days. We aimed to assess target engagement (primary end point: myeloperoxidase specific activity) and safety of AZD4831. Owing to coronavirus disease 2019, the study was terminated early after randomizing 41 patients (median age 74.0 years, 53.7% male). Myeloperoxidase activity was decreased by more than 50% from baseline to day 30 and day 90 in the AZD4831 group, with a placebo-adjusted decreased of 75% (95% confidence interval, 48, 88, nominal P < .001). No improvements were noted in secondary or exploratory end points, apart from a trend in Kansas City Cardiomyopathy Questionnaire overall summary score. No deaths or treatment-related serious adverse events occurred. AZD4831 treatment-related adverse events were generalized maculopapular rash, pruritus, and diarrhea (all n = 1).ConclusionsAZD4831 inhibited myeloperoxidase and was well tolerated in patients with heart failure and left ventricular ejection fraction of 40% or greater. Efficacy findings were exploratory owing to early termination, but warrant further clinical investigation of AZD4831.Lay SummaryFew treatments are available for patients with the forms of heart failure known as heart failure with preserved or mildly reduced ejection fraction. Current treatments do not target inflammation, which may play an important role in this condition. We tested a new drug called AZD4831 (mitiperstat), which decreases inflammation by inhibiting the enzyme myeloperoxidase. Among the 41 patients in our clinical trial, AZD4831 had a good safety profile and inhibited myeloperoxidase by the expected amount. Results mean we can conduct further trials to see whether AZD4831 decreases the symptoms of heart failure and improves patients’ ability to participate in physical exercise." @default.
• W4366000488 created "2023-04-17" @default.
• W4366000488 creator A5002789575 @default.
• W4366000488 creator A5005215114 @default.
• W4366000488 creator A5006006335 @default.
• W4366000488 creator A5013553039 @default.
• W4366000488 creator A5017341652 @default.
• W4366000488 creator A5024219403 @default.
• W4366000488 creator A5026153766 @default.
• W4366000488 creator A5026529813 @default.
• W4366000488 creator A5032419522 @default.
• W4366000488 creator A5039027696 @default.
• W4366000488 creator A5043224002 @default.
• W4366000488 creator A5045480084 @default.
• W4366000488 creator A5058239509 @default.
• W4366000488 creator A5067972379 @default.
• W4366000488 creator A5068373500 @default.
• W4366000488 creator A5069475935 @default.
• W4366000488 creator A5074566771 @default.
• W4366000488 creator A5077055608 @default.
• W4366000488 creator A5090618779 @default.
• W4366000488 date "2023-04-01" @default.
• W4366000488 modified "2023-10-17" @default.
• W4366000488 title "Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results" @default.
• W4366000488 cites W164205712 @default.
• W4366000488 cites W2427094903 @default.
• W4366000488 cites W2889002990 @default.
• W4366000488 cites W2911137869 @default.
• W4366000488 cites W3048320829 @default.
• W4366000488 cites W3134389911 @default.
• W4366000488 cites W4293101580 @default.
• W4366000488 cites W4367856890 @default.
• W4366000488 doi "https://doi.org/10.1016/j.cardfail.2023.04.003" @default.
• W4366000488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37072105" @default.
• W4366000488 hasPublicationYear "2023" @default.
• W4366000488 type Work @default.
• W4366000488 citedByCount "4" @default.
• W4366000488 countsByYear W43660004882023 @default.
• W4366000488 crossrefType "journal-article" @default.
• W4366000488 hasAuthorship W4366000488A5002789575 @default.
• W4366000488 hasAuthorship W4366000488A5005215114 @default.
• W4366000488 hasAuthorship W4366000488A5006006335 @default.
• W4366000488 hasAuthorship W4366000488A5013553039 @default.
• W4366000488 hasAuthorship W4366000488A5017341652 @default.
• W4366000488 hasAuthorship W4366000488A5024219403 @default.
• W4366000488 hasAuthorship W4366000488A5026153766 @default.
• W4366000488 hasAuthorship W4366000488A5026529813 @default.
• W4366000488 hasAuthorship W4366000488A5032419522 @default.
• W4366000488 hasAuthorship W4366000488A5039027696 @default.
• W4366000488 hasAuthorship W4366000488A5043224002 @default.
• W4366000488 hasAuthorship W4366000488A5045480084 @default.
• W4366000488 hasAuthorship W4366000488A5058239509 @default.
• W4366000488 hasAuthorship W4366000488A5067972379 @default.
• W4366000488 hasAuthorship W4366000488A5068373500 @default.
• W4366000488 hasAuthorship W4366000488A5069475935 @default.
• W4366000488 hasAuthorship W4366000488A5074566771 @default.
• W4366000488 hasAuthorship W4366000488A5077055608 @default.
• W4366000488 hasAuthorship W4366000488A5090618779 @default.
• W4366000488 hasBestOaLocation W43660004881 @default.
• W4366000488 hasConcept C126322002 @default.
• W4366000488 hasConcept C142724271 @default.
• W4366000488 hasConcept C164705383 @default.
• W4366000488 hasConcept C168563851 @default.
• W4366000488 hasConcept C197934379 @default.
• W4366000488 hasConcept C203092338 @default.
• W4366000488 hasConcept C203565725 @default.
• W4366000488 hasConcept C204787440 @default.
• W4366000488 hasConcept C27081682 @default.
• W4366000488 hasConcept C2776914184 @default.
• W4366000488 hasConcept C2778198053 @default.
• W4366000488 hasConcept C2778375690 @default.
• W4366000488 hasConcept C2778797674 @default.
• W4366000488 hasConcept C71924100 @default.
• W4366000488 hasConcept C78085059 @default.
• W4366000488 hasConceptScore W4366000488C126322002 @default.
• W4366000488 hasConceptScore W4366000488C142724271 @default.
• W4366000488 hasConceptScore W4366000488C164705383 @default.
• W4366000488 hasConceptScore W4366000488C168563851 @default.
• W4366000488 hasConceptScore W4366000488C197934379 @default.
• W4366000488 hasConceptScore W4366000488C203092338 @default.
• W4366000488 hasConceptScore W4366000488C203565725 @default.
• W4366000488 hasConceptScore W4366000488C204787440 @default.
• W4366000488 hasConceptScore W4366000488C27081682 @default.
• W4366000488 hasConceptScore W4366000488C2776914184 @default.
• W4366000488 hasConceptScore W4366000488C2778198053 @default.
• W4366000488 hasConceptScore W4366000488C2778375690 @default.
• W4366000488 hasConceptScore W4366000488C2778797674 @default.
• W4366000488 hasConceptScore W4366000488C71924100 @default.
• W4366000488 hasConceptScore W4366000488C78085059 @default.
• W4366000488 hasFunder F4320307770 @default.
• W4366000488 hasFunder F4320322783 @default.
• W4366000488 hasLocation W43660004881 @default.
• W4366000488 hasLocation W43660004882 @default.
• W4366000488 hasOpenAccess W4366000488 @default.
• W4366000488 hasPrimaryLocation W43660004881 @default.
• W4366000488 hasRelatedWork W1990197915 @default.
• W4366000488 hasRelatedWork W2087016115 @default.
• W4366000488 hasRelatedWork W2305775430 @default.
• W4366000488 hasRelatedWork W2427186628 @default.
• W4366000488 hasRelatedWork W2465571689 @default.

• next